Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: CXCL9 may serve as a potential biomarker for primary Sjögren’s syndrome with extra-glandular manifestations

Fig. 5

Differentially expressed CXCL9 in pSS subgroups with different EGM. A Box plot showing the expression of CXCL9 in pSS-EGM subgroups and pSS-non-EGM in MSGs. B Box plot showing the expression of CXCL9 in pSS-EGM subgroups and pSS-non-EGM in plasma. Significance determined by Kruskall-Wallis’s test. The “*” symbol denotes the significance between pSS-non-EGM and pSS-EGM subgroups. The “#” symbol denotes the significance between blood involvement and other subgroups within the pSS-EGM group. * p < 0.05, **p < 0.01, *** p < 0.001, **** p < 0.001; # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.001

Back to article page